SVRA
Savara Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Savara has 7 disclosed suppliers and 0 disclosed customers in SEC filings.
—
SentenceIn February 2024, we entered into a Master Services Agreement with FUJIFILM Diosynth Biotechnologies ("Fujifilm") to complete a technology transfer of the drug substance manufacturing process from GEMA Biotech S.A. ("GEMA") and to manufacture commercial supply of MOLBREEVI.
SVRA 10-Kaccession 0001193125-26-105076
SentenceIn April 2019, we entered into a manufacture and supply agreement with GEMA, which was amended on December 7, 2022 and December 13, 2023 (the "GEMA Agreement"), pursuant to which GEMA may supply the active pharmaceutical ingredient ("API") for MOLBREEVI exclusively to us for commercial sale and continue to supply the API to us for clinical trials and research and development activities.
SVRA 10-Kaccession 0001193125-26-105076
SentenceWe entered into a master services agreement ("Parexel MSA") with Parexel on March 5, 2021, pursuant to which Parexel provides contract research services related to our clinical trials.
SVRA 10-Kaccession 0001193125-26-105076
SentenceFor the supply of our exclusive, proprietary eFlow ® nebulizer system that is part of the MOLBREEVI drug-device combination, we have a long-term supply agreement in place with PARI.
SVRA 10-Kaccession 0001193125-26-105076
SentenceWe have entered into an agreement and related work orders with Patheon under which Patheon manufactures our MOLBREEVI product candidate for clinical trials.
SVRA 10-Kaccession 0001193125-26-105076
SentenceWe entered into a master services agreement with Selvita on January 17, 2024 (the "Selvita MSA") under which Selvita performs batch control testing and analyses of our MOLBREEVI drug product and drug substance through certain cell-based bioassays.
SVRA 10-Kaccession 0001193125-26-105076
SentenceWe partnered with TrilliumBiO, a modern health solutions provider and a Clinical Laboratory Improvement Amendments ("CLIA")-certified lab, to develop the test.
SVRA 10-Kaccession 0001193125-26-105076
Savara Inc
4.83
—
—
Largest filed tie
—
Expected move
No implied move.